Participated · Series A · Jun 2026

Hera combines an AI platform called Juno with a network of dedicated senior care experts—called Heroes, typically nurses and licensed social workers with geriatric experience—to manage non-clinical but essential caregiving tasks. Juno encodes tacit, local healthcare knowledge (for example provider availability, Medicaid approvals, and community resources) and learns from outcomes across families to improve recommendations. Since launching about a year ago, Hera has served ongoing care coordination for over 1,000 families with 95% retention. Hera works with referring physicians at major health systems including Weill Cornell, NYU Langone, Mount Sinai, USC and UCSF, and eligible Original Medicare beneficiaries access Hera's services at no out-of-pocket cost. The company is expanding geographically and hiring as it scales toward a goal of operating in 25+ states by year-end.

Participated · Equity · Jun 2026

Portal builds a proprietary mechanoporation-based platform to enable efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across diverse cell types and workflows. The company targets applications across novel drug discovery workflows, multi-perturbation AI data generation, and next-generation cell therapies, and integrates with high-throughput robotics and GMP manufacturing systems. Portal reports commercial traction with more than 100 customer sites, including public collaborations or use by Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue University. Use cases highlighted include high-throughput, physiologically relevant screening, generation of model-training biological data, and same-day circRNA-based multifunctional CAR-T production at the point of care. DARPA has expanded an initial $8M contract and is supporting commercialization through its EEI program, underscoring validation for Portal's point-of-care cell therapy manufacturing efforts. The company states it has achieved meaningful commercial revenue and technical validation from large pharma and academic partners.

Led · Seed · Apr 2026

Qualitate builds an AI-native intelligence platform whose AI moderator supports the full primary research workflow, including study design, expert recruitment, interview moderation and insight creation. The company positions its product for investor and corporate teams to run competitive intelligence, win/loss and churn studies, and to validate company traction or surface market signals. Its customer segments include enterprises, private equity, hedge funds and public-market investors, liquid credit and direct lending teams, and growth equity and venture capital firms. Qualitate is led by founder and CEO Sagar Kadakia and is based in New York City. The company raised a $7M Seed round in April 2026 and plans to use the capital to expand operations and continue product development. The announcement did not disclose revenue, user metrics or valuation.

Led · Seed · Feb 2026

Rapidata is an AI infrastructure company headquartered in Zurich, Switzerland. Founded and led by CEO Jason Corkill, the startup enables AI development teams to collect large volumes of human feedback through a global network of participants. Its platform leverages crowd intelligence to label, validate, and refine datasets used to train and evaluate machine-learning models, significantly reducing the time and cost of data annotation. The service positions Rapidata as a critical human-in-the-loop layer for higher-quality AI model performance. With new capital, the company plans to scale its worldwide human data network to meet rising demand from AI companies. The article did not disclose any revenue figures, user counts, or other operating metrics.

Participated · Series D · Sep 2025

Enveda is a clinical-stage biotechnology company that learns from life’s chemistry to create small-molecule therapeutics using AI-powered metabolomics and a proprietary chemical sequencer. The platform makes previously inaccessible natural chemistry searchable and uses automation to map therapeutic properties at high throughput. Enveda says it delivers 12+ development candidates 4× faster and 10× cheaper than industry averages and has built one of the world’s largest collections of natural samples. Its pipeline includes sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program. ENV-294, the lead program, is a first-in-class oral anti-inflammatory small molecule discovered on the platform and has moved into a Phase 1b trial after favorable Phase 1a results; Enveda has enrolled the first patient. The company recently raised additional capital and added industry veteran Dr. Mikael Dolsten to its board to support clinical advancement across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and other indications. Enveda harnesses AI-powered tools to identify and characterize molecules produced by living organisms, building a database of chemical biodiversity it calls the library of life. Its platform integrates computational methods with deep chemical and biological insights to uncover novel mechanisms of action and drug candidates. The company has advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, into clinical trials and highlights the potential for a safe, effective oral therapy in immunology and inflammation. Enveda plans to expand its clinical pipeline in 2025 and further enhance its AI-driven discovery capabilities. The company frames its approach as metabolite-driven drug development aimed at delivering medicines faster by learning from evolved solutions in nature. Enveda is a biotechnology company that uses an AI-powered platform combining metabolomics, machine learning, and automated high-throughput laboratory workflows to translate natural compounds into drug candidates. Its platform has characterized the structure and function of over 1 million natural compounds, creating the largest known natural product dataset custom-built for modern drug discovery. The company says this approach answers what molecules are and what they do at scale and enables discovery roughly four times faster than historical averages. Enveda’s pipeline includes 10 Development Candidates across immunology & inflammation, obesity, fibrosis, and neurosensory indications. The company recently received IND clearance for ENV-294, which entered Phase I at the end of October. The new funding will support multiple clinical catalysts in 2025 and 2026 and further investment in the platform and discovery programs. Enveda Biosciences, founded in 2019 and based in Boulder, Colorado, combines AI with ethnobotanical knowledge to identify medicinal molecules from plants. The company has assembled a database of about 38,000 medicinal plants linked to roughly 12,000 diseases and symptoms. Using a transformer model that deciphers the "chemical language" of whole samples, Enveda prioritizes sets of molecules for development rather than studying single compounds in isolation. That platform has produced near-term assets: two drugs (one for skin conditions including eczema, and one for inflammatory bowel diseases) are expected to enter clinical trials later this year. Financially, the company has raised capital that totals $230 million to date and plans to pursue a Series C after the start of those clinical trials. Enveda builds a proprietary platform that combines large language models, metabolomics, and robotics to create a high-resolution chemical map of nature and search nature’s chemical space for drug discovery. The platform addresses long-standing obstacles in natural product drug development, including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. Enveda pairs this technology with experienced drug hunters and data scientists to advance platform-derived molecules. The company plans to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications. Financially, Enveda has been raising growth capital to advance its pipeline and platform and recently completed additional financing to support clinical progress. For more information, Enveda directs readers to envedabio.com.